European multicentre study initiated for 5 years’ follow-up of Episealer® Knee patients
Episurf Medical (Nasdaq: EPIS B) today announces the initiation of an investigator-initiated European multicentre study with 5 years’ follow-up of 50 Episealer® Knee patients. The study is a continuation of the European multicentre study, from which 2 years’ follow-up results were published in September 2020 (Holz, J. et al, Patient‑specific metal implants for focal chondral and osteochondral lesions in the knee; excellent clinical results at 2 years, KSSTA online 2020). The interim study from 2020 concluded that the results indicate that there is a definitive place for the Episealer®